Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's lorazepam 2 mg
tablets to Wyeth's Ativan 2 mg tablets following a single, oral 2 mg (1 x 2 mg) dose
administered under fasting conditions.